These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34247911)

  • 41. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
    Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study.
    Wong CKH; Lau KTK; Tang EHM; Lee CH; Lee CYY; Woo YC; Au ICH; Tan KCB; Lui DTW
    Cardiovasc Diabetol; 2022 Jun; 21(1):92. PubMed ID: 35658864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
    Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
    Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.
    Luo J; Gabriel N; Korytkowski M; Hernandez I; Gellad WF
    Diabetes Res Clin Pract; 2022 May; 187():109855. PubMed ID: 35346753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.
    Fadah K; Alashi A; Deoker A
    Curr Cardiol Rep; 2022 Jan; 24(1):17-22. PubMed ID: 35000149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.
    Wu T; Wong CKH; Tang EHM; Man KKC; Wong SKH; Au ICH; Tse ETY; Chan EWY; Grieve E; Wu O; Ng EKW; Wong ICK
    Surg Obes Relat Dis; 2022 Jun; 18(6):762-771. PubMed ID: 35300912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.
    Consoli A; Formoso G; Baldassarre MPA; Febo F
    Expert Opin Drug Saf; 2018 Mar; 17(3):293-302. PubMed ID: 29334278
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community-based study.
    Williams BA; Brady JP; Voyce S; Kumar N; Paprocki Y; Rajpura J
    Diabetes Obes Metab; 2022 Jul; 24(7):1216-1223. PubMed ID: 35257457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.
    Yang YS; Chen HH; Huang CN; Hsu CY; Hu KC; Kao CH
    Diabetes Care; 2022 May; 45(5):1184-1192. PubMed ID: 35275992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
    Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
    Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.